Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease

Kidney International

Volumn 84, Issue 5, 2013, Pages 1017-1024

  Barbour, Sean J ^a,b,c   Cattran, Daniel C ^c,d   Kim, S Joseph ^d   Levin, Adeera ^a,b   Wald, Ron ^d   Hladunewich, Michelle A ^c,d   Reich, Heather N ^c,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b British Columbia Provincial Renal Agency   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

end stage renal disease; ethnicity; IgA nephropathy; progression of renal failure; renal progression

Indexed keywords

ADULT; ARTICLE; ASIAN; BLOOD PRESSURE MEASUREMENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RISK ASSESSMENT; RISK FACTOR; SELF REPORT;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CANADA; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, IGA; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RENAL DIALYSIS; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84888325641     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.210     Document Type: Article

References (28)

1. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2002; 347: 738-748.
2. Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol 2005; 16: 2088-2097.
3. McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant 2011; 26: 414-430.
4. Hall YN, Fuentes EF, Chertow GM et al. Race/ethnicity and disease severity in IgA nephropathy. BMC Nephrol 2004; 5: 10.
5. Nair R, Walker PD. Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA Kidney Int 2006; 69: 1455-1458.
6. Cattran D, Reich H. Chapter 33Overview of therapy for glomerular diseases. In: Taal M, Chertow G, Marsden P, Skorecki K, Yu A, Breener B (eds). Brenner and Rector's The Kidney, 9th edn. Elsevier Saunders: Philadelphia, 2012, pp 1278-1292.
7. Statistics CanadaThe Daily: Canada's visible minority population in 2017. http://www.statcan.gc.ca/daily-quotidien/050322/dq050322b-eng.htm.
8. Canadian Institute for Health Information 2010 Annual Report-Treatment of End-Stage Organ Failure in Canada, 1999 to 2008. www.kidney.ca/document.docid=855.
9. US Renal Data SystemUSRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2011.
10. Cai GY, Chen XM. Immunoglobulin A nephropathy in China: progress and challenges. Am J Nephrol 2009; 30: 268-273.
11. US Renal Data System. USRDS 2002 annual data report: atlas of end-stage renal disease in the United States. National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD, 2002.
12. Bartosik LP, Lajoie G, Sugar L et al. Predicting progression in IgA nephropathy. Am J Kidney Dis 2001; 38: 728-735.
13. Reich HN, Troyanov S, Scholey JW et al. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 2007; 18: 3177-3183.
14. Ma YC, Zuo L, Chen JH et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006; 17: 2937-2944.
15. Hastings MC, Moldoveanu Z, Julian BA et al. Galactose-deficient IgA1 in African Americans with IgA nephropathy: serum levels and heritability. Clin J Am Soc Nephrol 2010; 5: 2069-2074.
16. Lin X, Ding J, Zhu L et al. Aberrant galactosylation of IgA1 is involved in the genetic susceptibility of Chinese patients with IgA nephropathy. Nephrol Dial Transplant 2009; 24: 3372-3375.
17. Gharavi AG, Moldoveanu Z, Wyatt RJ et al. Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol 2008; 19: 1008-1014.
18. Suzuki K, Honda K, Tanabe K et al. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 2003; 63: 2286-2294.
19. Gharavi AG, Kiryluk K, Choi M et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 2011; 43: 321-327.
20. Cattran DC, Coppo R, Cook HT et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76: 534-545.
21. Bostrom MA, Freedman BI. The spectrum of MYH9-associated nephropathy. Clin J Am Soc Nephrol 2010; 5: 1107-1113.
22. Barbour SJ, Er L, Djurdjev O et al. Differences in progression of CKD and mortality amongst Caucasian, Oriental Asian and South Asian CKD patients. Nephrol Dial Transplant 2010; 25: 3663-3672.
23. Central Committee of the Toronto Glomerulonephritis Registry. Regional program for the study of glomerulonephritis. Can Med Assoc J 1981; 124: 158-161.
24. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
25. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 Suppl 1): S1-S266.
26. Mackinnon B, Fraser EP, Cattran DC et al. Validation of the Toronto formula to predict progression in IgA nephropathy. Nephron Clin Pract 2008; 109: c148-c153.
27. Barbour SJ, Reich HN. Risk stratification of patients with IgA nephropathy. Am J Kidney Dis 2012; 59: 865-873.
28. Vittinghoff E, Glidden D, Shiboski S et al. Regression Methods in Biostatistics. Springer Science: New York, 2010.